NCI Division of Cancer Prevention shared on LinkedIn:
“New Funding Opportunity! This NOFO is to support rigorous development and validation of Digital Health Technology (DHT) derived biomarkers or clinical outcome assessments (COAs) for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials. This includes development and validation of digital biomarkers to monitor cancer treatment related symptoms, sequelae, and/or outcomes (e.g., pain, cognitive impairment, adverse events, late effects toxicity). PAR-25-170
Expires: June 23, 2026.”
